ReviewBiochemistry and biophysics reports2026
O-GlcNAcylation: A bridge for regulating the function of the "heart-kidney-bone axis".
Review in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The three major organ systems of heart, kidney and bone are highly correlated in physiology and pathology. They form the "heart-kidney-bone axis" together. The typical clinical manifestations of this axis include the deterioration of heart and kidney function, reflected by cardiorenal syndrome, renal bone disease, and cardiovascular calcification contained in chronic kidney disease-mineral bone disorder (CKD-MBD). However, the core molecular mechanism that regulates this axis has not been fully understood. O-linked N-acetylglucosamine (O-GlcNAc) glycosylation modification is a dynamic, reversible and highly conserved protein post-translational modification (PTM). It integrates body nutrition and stress signals via the hexosamine biosynthesis pathway (HBP), extensively participates in fine cellular function regulation, and plays an essential role in the progression of heart, kidney and bone diseases. This review systematically summarizes the role and multidimensional regulatory network characteristics of O-GlcNAcylation in heart, kidney and skeletal systems. It focuses on exploring its cross-organ regulatory mechanism in the "heart-kidney-bone axis", and aims to provide new ideas for the mechanism analysis and targeted therapy of comorbidities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.